Pharmacokinetics, tissue distribution and excretion of 40 kDa PEG and PEGylated rFVIII (N8-GP) in rats

European Journal of Pharmaceutical Sciences

Volumn 87, Issue , 2016, Pages 58-68

  Bjørnsdottir, Inga ^a   Sternebring, Ola ^a   Kappers, Wendela A ^a   Selvig, Helle ^a   Kornø, Hanne T ^a   Kristensen, Jesper B ^a   Bagger, Morten A ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Distribution; Excretion; N8 GP; PEGylated rFVIII; Pharmacokinetics

Indexed keywords

MACROGOL; RECOMBINANT BLOOD CLOTTING FACTOR 8; TRITIUM; BLOOD CLOTTING FACTOR 8; MACROGOL DERIVATIVE; N8-GP COMPOUND; TRACER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG EXCRETION; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; NONHUMAN; PHARMACOKINETIC PARAMETERS; PLASMA CLEARANCE; PRIORITY JOURNAL; RADIOACTIVITY; RAT; TISSUE DISTRIBUTION; URINARY EXCRETION; ANIMAL; DOSE RESPONSE; HALF LIFE TIME;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIII; HALF-LIFE; MALE; POLYETHYLENE GLYCOLS; RADIOACTIVE TRACERS; RATS; TISSUE DISTRIBUTION;

EID: 84947998826     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2015.10.020     Document Type: Article

References (35)

1. MASAC Recommendation Concerning Prophylaxis. Document #179 Medical and Scientific Advisory Council http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contenid=1007 2007
2. H. Agerso, H.R. Stennicke, H. Pelzer, E.N. Olsen, E.P. Merricks, N.A. Defriess, T.C. Nichols, and M. Ezban Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs Haemophilia 18 2012 941 947
3. P. Bailon, and C.Y. Won PEG-modified biopharmaceuticals Expert Opin. Drug Deliv. 6 2009 1 16
4. A. Baumann, D. Tuerck, S. Prabhu, L. Dickmann, and J. Sims Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis? Drug Discov. Today 19 2014 1623 1631
5. S. Bjorkman, and E. Berntorp Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia Clin. Pharmacokinet. 40 2001 815 832
6. S. Bjorkman, A. Folkesson, and S. Jonsson Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A Eur. J. Clin. Pharmacol. 65 2009 989 998
7. N. Bovenschen, J. Herz, J.M. Grimbergen, P.J. Lenting, L.M. Havekes, K. Mertens, and B.J. van Vlijmen Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency Blood 101 2003 3933 3939
8. Y. Cai, Z. Zhang, K. Fan, J. Zhang, W. Shen, M. Li, D. Si, H. Luo, Y. Zeng, P. Fu, and C. Liu Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-alpha variant in monkeys, rats and guinea pigs Regul. Pept. 173 2012 74 81
9. P. Caliceti, and F.M. Veronese Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates Adv. Drug Deliv. Rev. 55 2003 1261 1277
10. M.L. Christiansen, K.W. Balling, E. Persson, I. Hilden, A. Bagger-Sorensen, B.B. Sorensen, D. Viuff, S. Segel, N.K. Klausen, M. Ezban, S. Lethagen, T.D. Steenstrup, and M. Kjalke Functional characteristics of N8, a new recombinant FVIII Haemophilia 16 2010 878 887
11. A. Coppola, C.M. Di, and S.C. De Primary prophylaxis in children with haemophilia Blood Transfus. 6 Supplement 2 2008 S4 11
12. A. Coppola, and M. Franchini Target of prophylaxis in severe haemophilia: more than factor levels Blood Transfus. 11 2013 327 329
13. S. DeFrees, Z.G. Wang, R. Xing, A.E. Scott, J. Wang, D. Zopf, D.L. Gouty, E.R. Sjoberg, K. Panneerselvam, E.C. Brinkman-Van der Linden, R.J. Bayer, M.A. Tarp, and H. Clausen GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli Glycobiology 16 2006 833 843
14. V.L. Elliott, G.T. Edge, M.M. Phelan, L.Y. Lian, R. Webster, R.F. Finn, B.K. Park, and N.R. Kitteringham Evidence for metabolic cleavage of a PEGylated protein in vivo using multiple analytical methodologies Mol. Pharm. 9 2012 1291 1301
15. J.M. Harris, and R.B. Chess Effect of pegylation on pharmaceuticals Nat. Rev. Drug Discov. 2 2003 214 221
16. C.R. Hay Prophylaxis in adults with haemophilia Haemophilia 13 Supplement 2 2007 10 15
17. I.A. Ivens, A. Baumann, T.A. McDonald, T.J. Humphries, L.A. Michaels, and P. Mathew PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers Haemophilia 19 2013 11 20
18. L.M. Kaminskas, D.B. Ascher, V.M. McLeod, M.J. Herold, C.P. Le, E.K. Sloan, and C.J. Porter PEGylation of interferon alpha2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases J. Control. Release 168 2013 200 208
19. J. Lamka, O. Schiavon, M. Laznicek, P. Caliceti, and F.M. Veronese Distribution of catalase, ribonuclease and superoxide dismutase modified by monomethoxy (polyethylene glycol) into rat central lymph and lymphatic nodes Physiol. Res. 44 1995 307 313
20. J. Malmstrom Characterization of 40 kDa poly(ethylene glycol) polymers by proton transfer reaction QTOF mass spectrometry and 1H-NMR spectroscopy Anal. Bioanal. Chem. 403 2012 1167 1177
21. B. Mei, C. Pan, H. Jiang, H. Tjandra, J. Strauss, Y. Chen, T. Liu, X. Zhang, J. Severs, J. Newgren, J. Chen, J.M. Gu, B. Subramanyam, M.A. Fournel, G.F. Pierce, and J.E. Murphy Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment Blood 116 2010 270 279
22. R. Nakaoka, Y. Tabata, T. Yamaoka, and Y. Ikada Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification J. Control. Release 46 1997 253 261
23. A.M. Nesbitt, S. Stephens, and E.K. Chartash Certolizumab Pegol: A PEgylated Anti-Tumour Necrosis Factor Alpha Biological Agent PEGylated Protein Drugs: Basic Science and Clinical Applications 2009
24. I.M. Nilsson, E. Berntorp, T. Lofqvist, and H. Pettersson Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B J. Intern. Med. 232 1992 25 32
25. E.L. Saenko, A.V. Yakhyaev, I. Mikhailenko, D.K. Strickland, and A.G. Sarafanov Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism J. Biol. Chem. 274 1999 37685 37692
26. A. Srivastava, A.K. Brewer, E.P. Mauser-Bunschoten, N.S. Key, S. Kitchen, A. Llinas, C.A. Ludlam, J.N. Mahlangu, K. Mulder, M.C. Poon, and A. Street Guidelines for the management of hemophilia Haemophilia 19 2013 e1 47
27. H.R. Stennicke, M. Kjalke, D.M. Karpf, K.W. Balling, P.B. Johansen, T. Elm, K. Ovlisen, F. Moller, H.L. Holmberg, C.N. Gudme, E. Persson, I. Hilden, H. Pelzer, H. Rahbek-Nielsen, C. Jespersgaard, A. Bogsnes, A.A. Pedersen, A.K. Kristensen, B. Peschke, W. Kappers, F. Rode, L. Thim, M. Tranholm, M. Ezban, E.H. Olsen, and S.E. Bjorn A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models Blood 121 2013 2108 2116
28. D.K. Strickland, D.T. Au, P. Cunfer, and S.C. Muratoglu Low-density lipoprotein receptor-related protein-1: role in the regulation of vascular integrity Arterioscler. Thromb. Vasc. Biol. 34 2014 487 498
29. A. Tiede, B. Brand, R. Fischer, K. Kavakli, S.R. Lentz, T. Matsushita, C. Rea, K. Knobe, and D. Viuff Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A J. Thromb. Haemost. 11 2013 670 678
30. P.L. Turecek, M.J. Bossard, M. Graninger, H. Gritsch, W. Hollriegl, M. Kaliwoda, P. Matthiessen, A. Mitterer, E.M. Muchitsch, M. Purtscher, H. Rottensteiner, A. Schiviz, G. Schrenk, J. Siekmann, K. Varadi, T. Riley, H.J. Ehrlich, H.P. Schwarz, and F. Scheiflinger BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation Hamostaseologie 32 Supplement 1 2012 S29 S38
31. R. Webster, E. Didier, P. Harris, N. Siegel, J. Stadler, L. Tilbury, and D. Smith PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies Drug Metab. Dispos. 35 2007 9 16
32. R. Webster, V. Elliott, B.K. Park, D. Walker, M. Hankin, and P. Taupin PEG and PEG Conjugates Toxicity: Towards an Understanding of the Toxicity of PEG and its Relevance to PEGylated Biologicals PEGylated Protein Drugs: Basic Science and Clinical Applications 2009
33. K.W. Woodburn, K.L. Fong, S.D. Wilson, S. Sloneker, P. Strzemienski, E. Solon, Y. Moriya, and Y. Tagawa Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration Drug Metab. Dispos. 41 2013 774 784
34. T. Yamaoka, Y. Tabata, and Y. Ikada Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice J. Pharm. Sci. 83 1994 601 606
35. Y. Zou, T.J. Bateman, C. Adreani, X. Shen, P.K. Cunningham, B. Wang, T. Trinh, A. Christine, X. Hong, C.N. Nunes, C.V. Johnson, A.S. Zhang, S.J. Staskiewicz, M. Braun, S. Kumar, and V.B. Reddy Lymphatic absorption, metabolism, and excretion of a therapeutic peptide in dogs and rats Drug Metab. Dispos. 41 2013 2206 2214